|1.||Calcinai, E: 1 article (01/2010)|
|2.||Terracciano, L: 1 article (01/2010)|
|3.||Fiocchi, A: 1 article (01/2010)|
|4.||Beghi, G: 1 article (01/2010)|
|5.||Honjoh, Tsutomu: 1 article (05/2009)|
|6.||Fukui, Masayuki: 1 article (05/2009)|
|7.||Shinomiya, Takahisa: 1 article (05/2009)|
|8.||Nagahara, Yukitoshi: 1 article (05/2009)|
|9.||Nishio, Yoshiaki: 1 article (05/2009)|
|10.||Shin, Ho-Joon: 1 article (11/2008)|
02/01/1990 - "Because Campylobacter jejuni is most frequently identified as a causative organism of bacterial enteritis in pediatrics, a study was done to evaluate the clinical efficacy against Campylobacter enteritis and the safety of a macrolide antibiotic, rokitamycin (RKM). "
10/01/1991 - "[In vitro antimicrobial activity of rokitamycin, a macrolide antibacterial agent, against clinically isolated strains of Campylobacter and other enteritis-causing bacteria]."
09/01/1991 - "The Research Committee for the Effect of Rokitamycin, Research Group for Infectious Enteritis]."
09/01/1991 - "Rokitamycin was considered clinically useful to treat Campylobacter enteritis."
09/01/1991 - "Rokitamycin, a newly developed macrolide, was administered to a total of 107 cases, 16 years old or more, in order to evaluate its clinical efficacy, safety and usefulness on Campylobacter enteritis. "
10/01/1988 - "[Clinical studies of rokitamycin dry syrup on Chlamydia trachomatis infections in the neonate and infant]."
07/01/1988 - "[A clinical study of rokitamycin dry syrup in pediatric infections]."
06/01/1988 - "[Studies on efficacy, safety and dosage of rokitamycin in the treatment of pediatric infections]."
06/01/1988 - "In a study of rokitamycin (RKM) dry syrup for its usefulness in pediatric infections, the following results were obtained: 1. Frequencies of RKM-resistant strains among fresh isolates from sick children were very low, and 4.4% of 68 isolates of Staphylococcus aureus, 4.2% of 48 isolates of Streptococcus pneumoniae, and none of 96 isolates of Streptococcus pyogenes were found to be RKM-resistant. "
05/01/2003 - "Treatment with rokitamycin suppresses the lethality in a murine model of Escherichia coli O157:H7 infection."
12/01/1990 - "In this study, we evaluated the efficacy of Rokitamycin, a 16-membered ring macrolide antibiotic agent, in the treatment of tonsillitis associated with C. "
12/01/1990 - "[Tonsillitis associated with Chlamydia trachomatis and antimicrobial therapy with rokitamycin]."
01/01/2010 - "To review current clinical evidence for the use of antibiotics in paediatric upper paediatric respiratory infections, repeated PubMed searches using the template algorithm -rhinosinusitis/otitis/ tonsillitis AND ()- with the settings: -Humans; English; All Child 0-18; Clinical trial; Review; Methanalysis; Guideline; Last 10 years- for the following comparators: antibiotic; amoxicillin; clavulanate; penicillin; cephalosporin; macrolide; erythromycin; rokitamycin; clindamycin; trimethoprim-sulfamethoxazole, cefopodoxime, cefdinir, cefuroxime, ceftriaxone. "
|5.||Soft Tissue Infections
10/01/1988 - "[Clinical studies of rokitamycin dry syrup on skin and soft tissue infections in the pediatric fields]."
03/01/1985 - "[Clinical and bacteriological evaluation of TMS-19-Q in superficial suppurative skin and soft tissue infection]."
10/01/1988 - "Rokitamycin (RKM) dry syrup, a newly developed macrolide antibiotic, was administered to children with ages between 6 months and 15 years and 10 months suffering from skin and soft tissue infections including 41 cases of impetigo, one case of staphylococcal scalded skin syndrome (SSSS) and 2 cases of subcutaneous abscess totalling 44 cases. "
|2.||Anti-Bacterial Agents (Antibiotics)
|3.||Josamycin (EN 141)
|5.||Secretory Immunoglobulin A (SIgA)